pharm edaily

[Song Young doo. Edaily Reporter] Korean medical AI company Lunit announced on the 22nd that it has entered into a strategic collaboration with Agilent Technologies, a global biotechnology company, to co-develop artificial intelligence(AI)-based companion diagnostic(CDx) solutions.

Agilent, headquartered in California, is a global leader in the biotechnology and applied chemical markets. The company provides a broad range of analytical solutions essential for pharmaceutical and biotech firms during the drug development process. With annual revenue of approximately $6.5 billion, Agilent is regarded as one of the world’s top life science companies, alongside Thermo Fisher Scientific, Danaher, and Illumina.

The collaboration focuses on combining Lunit’s advanced AI technology with Agilent’s tissue-based diagnostic expertise to jointly develop and commercialize next-generation solutions that address the growing demand for biomarker analysis in drug development.

In the initial phase, the two companies will concentrate on developing AI solutions applicable to early-stage clinical trials. Over the long term, the partnership aims to expand into regulatory approval and commercialization of AI-powered companion diagnostics for global pharmaceutical companies developing oncology drugs.

Through this collaboration, Lunit plans to strengthen its position in the global CDx market and establish AI-powered pathology analysis solutions, such as Lunit SCOPE, as global standards in precision medicine.

“Biomarker testing is a cornerstone of precision oncology, yet much of it still relies heavily on manual analysis,” said Lunit CEO Brandon Suh. “By combining Agilent’s global diagnostic platform with Lunit’s validated AI pathology technology, pharmaceutical companies will be able to bring new drugs to market with greater accuracy and speed than ever before.”

Nina Green, Vice President and General Manager of Agilent’s Clinical Diagnostics Division, added, “Agilent has long focused on delivering state-of-the-art diagnostic solutions for pharma and patients. Through this collaboration with Lunit, we will develop innovative AI-powered companion diagnostic solutions that can serve as a driving force for the global expansion of precision medicine.”

Lunit expects the partnership with Agilent to broaden collaboration opportunities with global pharmaceutical companies, while actively converting outcomes from clinical and research-stage collaborations into revenue streams. This strategy is designed to secure a new growth foundation in the global cancer treatment market.